Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

Impact · against what's priced in

The article suggests a significant bullish gap between Maze Therapeutics' current market price and analyst valuations. While the upward trend in earnings revisions and price targets provides a positive fundamental signal, the current price is just beginning to react to these expectations.

MAZE+0.50: No priced-in read yet

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

What matters in this story

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

What matters in this story

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

How each ticker is affected

Track these names every morning.

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

LuxExperience B.V. - Sponsored ADR (LUXE)'s Technical Outlook is Bright After Key Golden Cross

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

What matters in this story

Next reads from the same story arc

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

What matters in this story

Next reads from the same story arc

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

How each ticker is affected

Track these names every morning.

PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know

LuxExperience B.V. - Sponsored ADR (LUXE)'s Technical Outlook is Bright After Key Golden Cross

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology